Advertisement

Antipsychotika

  • M. J. Müller
  • O. Benkert

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Antipsychotika im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben. Ein Schwerpunkt liegt in der ausführlichen Darstellung der Risiken und Nebenwirkungen der Antipsychotika. Lorazepam und Loxapin sind als neue Antipsychotika eingeführt.

Literatur

  1. Arranz B, Garriga M, García-Rizo C, San L (2018) Clozapine use in patients with schizophrenia and a comorbid substance use disorder: a systematic review. Eur Neuropsychopharmacol 28(2): 227–242CrossRefGoogle Scholar
  2. Block TS, Kushner H, Kalin N et al (2018) Combined analysis of mifepristone for psychotic depression: plasma levels associated with clinical response. Biol Psychiatry pii: S0006–3223(18)30035-0Google Scholar
  3. Berling I, Isbister GK (2015) Prolonged QT risk assessment in antipsychotic overdose using the QT nomogram. Ann Emerg Med 66(2): 154–164CrossRefGoogle Scholar
  4. Borlido C, Remington G, Graff-Guerrero A et al (2016) Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized double-blind, placebo-controlled study. J Clin Psychiatry 77: e14–20Google Scholar
  5. Combs BL, Cox AG (2017) Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin. Neuropsychiatr Dis Treat 13: 737–744Google Scholar
  6. Correll CU, Joffe BI, Rosen LM et al (2015) Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study. World Psychiatry 14: 56–63CrossRefGoogle Scholar
  7. Correll CU, Rubio JM, Inczedy-Farkas G et al (2017) Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 74(7): 675–684CrossRefGoogle Scholar
  8. Demjaha A, Lappin JM, Stahl D et al (2017) Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med 47(11): 1981–1989CrossRefGoogle Scholar
  9. DGPPN (Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde) (Hrsg) (2006) Behandlungsleitlinie Schizophrenie. Reihe: S3 Praxisleitlinien in Psychiatrie und Psychotherapie, Bd 1. Springer, Berlin Heidelberg New York (Die Aktualisierung der Leitlinie und die Überführung in eine kombinierte S3-Leitlinie / Nationale Versorgungsleitlinie (NVL) ist bis Ende 2018 vorgesehen; https://www.awmf.org/leitlinien/detail/anmeldung/1/ll/nvl-010.html; zuletzt abfgerufen am 14.06.2018)
  10. Dold M, Li C, Gillies D, Leucht S (2013) Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol 23: 1023–1033CrossRefGoogle Scholar
  11. Dunk LR, Annan LJ, Andrews CD (2006) Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 188: 255–263CrossRefGoogle Scholar
  12. Fink A, Cieslak S, Rosenbach F (2015) Nichtpharmakologische Interventionen zur Prävention von Gewichtszunahme bei schizophrenen Patienten unter antipsychotischer Medikation. Psychiat Prax 42: 359–369CrossRefGoogle Scholar
  13. Fusar-Poli P, McGorry PD, Kane JM (2017) Improving outcomes of first-episode psychosis: an overview. World Psychiatry 16(3): 251–265CrossRefGoogle Scholar
  14. Furukawa TA, Levine SZ, Tanaka S et al (2015) Initial severity of schizophrenia and efficacy of antipsychotics. JAMA Psychiatry 72: 14–21CrossRefGoogle Scholar
  15. Gallego JA, Bonetti J, Zhang J et al (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138: 18–28CrossRefGoogle Scholar
  16. Galling B, Roldán A, Rietschel L et al (2016) Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf 15(5): 591–612Google Scholar
  17. Glick ID, Davis JM, Zamora D et al (2017) Should antipsychotic medications for schizophrenia be given for a lifetime? A naturalistic, long-term follow-up study. J Clin Psychopharmacol 37(2): 125–130CrossRefGoogle Scholar
  18. Gregory A, Mallikarjun P, Upthegrove R (2017) Treatment of depression in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 211(4): 198–204CrossRefGoogle Scholar
  19. Gründer G, Heinze M, Cordes J et al; NeSSy Study Group (2016) Effects of first-generation antipsychotics versus second-generation antipsychotics on quality of life in schizophrenia: a double-blind, randomised study. Lancet Psychiatry 3(8): 717–729Google Scholar
  20. Jauhar S, McKenna PJ, Radua J et al (2014) Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 204: 20–29CrossRefGoogle Scholar
  21. Helfer B, Samara MT, Huhn M et al (2016) Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 173(9): 876–886CrossRefGoogle Scholar
  22. Howes OD, McCutcheon R, Agid O et al (2017) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 174(3): 216–229Google Scholar
  23. Kane JM, Correll CU (2016) The role of clozapine in treatment-resistant schizophrenia. JAMA Psychiatry 73(3): 187–188CrossRefGoogle Scholar
  24. Keating D, McWilliams S, Schneider I et al (2017) Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open 7(1): e013881CrossRefGoogle Scholar
  25. Kennedy NI, Lee WH, Frangou S (2018) Efficacy of non-invasive brain stimulation on the symptom dimensions of schizophrenia: a meta-analysis of randomized controlled trials. Eur Psychiatry 49: 69–77CrossRefGoogle Scholar
  26. Knöchel C, Reuter J, Reinke B et al (2016) Cortical thinning in bipolar disorder and schizophrenia. Schizophr Res 172(1–3): 78–85CrossRefGoogle Scholar
  27. Lally J, Tully J, Robertson D et al (2016) Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 171(1–3): 215–224CrossRefGoogle Scholar
  28. Lambert M, Niehaus V, Correll C (2016) Pharmacotherapy in children and adolescents at clinical-high risk for psychosis and bipolar disorder. Pharmacopsychiatry 49(6): 229–244CrossRefGoogle Scholar
  29. Lederbogen F, Schwarz P, Häfner S et al (2015) Kardiale und metabolische Risikofaktoren bei schweren psychischen Erkrankungen. Nervenarzt 86: 866–871CrossRefGoogle Scholar
  30. Leucht S, Davis JM (2017) Do antipsychotic drugs lose their efficacy for relapse prevention over time? Br J Psychiatry 211(3): 127–129CrossRefGoogle Scholar
  31. Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382(9896): 951–962CrossRefGoogle Scholar
  32. Leucht S, Samara M, Heres S et al (2014) Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 40(2): 314–326CrossRefGoogle Scholar
  33. Leucht S, Leucht C, Huhn M et al (2017) Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 174(10): 927–942CrossRefGoogle Scholar
  34. Mahmood S, Booker I, Huang J, Coleman CI (2013) Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol 33: 90–94CrossRefGoogle Scholar
  35. Masood B, Lepping P, Romanov D, Poole R (2018) Treatment of alcohol-induced psychotic disorder (alcoholic hallucinosis) – a systematic review. Alcohol Alcohol 53(3): 259–267CrossRefGoogle Scholar
  36. Maust DT, Kim HM, Seyfried LS et al (2015) Antipsychotics, other psychotropics, and the risk of death in patients with dementia. JAMA Psychiatry 72: 438–445CrossRefGoogle Scholar
  37. Mayoral-van Son J, de la Foz VO, Martinez-Garcia O et al (2016) Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J Clin Psychiatry 77(4): 492–500Google Scholar
  38. Morgan CJA, Freeman TP, Powell J et al (2016) AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers. Transl Psychiatry 6: e738CrossRefGoogle Scholar
  39. Osoegawa C, Gomes JS, Grigolon RB et al (2018) Non-invasive brain stimulation for negative symptoms in schizophrenia: an updated systematic review and meta-analysis. Schizophr Res pii: S0920–9964(18)30031-8Google Scholar
  40. Pelzer AC, van der Heijden FM, den Boer E (2018) Systematic review of catatonia treatment. Neuropsychiatr Dis Treat 14: 317–326CrossRefGoogle Scholar
  41. Pillinger T, Beck K, Gobjila C et al (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74(3): 261–269CrossRefGoogle Scholar
  42. Samara MT, Leucht C, Leeflang MM et al (2015) Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 172: 617–629CrossRefGoogle Scholar
  43. Samara MT, Dold M, Gianatsi M et al (2016) Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry 73(3): 199–210CrossRefGoogle Scholar
  44. Siskind D, McCartney L, Goldschlager R, Kisely S (2016) Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 209(5): 385CrossRefGoogle Scholar
  45. Solmi M, Murru A, Pacchiarotti I et al (2017) Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag 13: 757–777CrossRefGoogle Scholar
  46. Sondergaard KB, Weeke P, Wissenberg M et al (2017) Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J Cardiovasc Pharmacother 3(2): 100–107Google Scholar
  47. Taylor DM, Smith L, Gee SH et al (2012) Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 125: 15–24CrossRefGoogle Scholar
  48. Tiihonen J, Mittendorfer-Rutz E, Torniainen M et al (2016) Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study. Am J Psychiatry 173(6): 600–606CrossRefGoogle Scholar
  49. Tiihonen J, Mittendorfer-Rutz E, Majak M et al (2017) Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29.823 patients with schizophrenia. JAMA Psychiatry 74(7): 686–693CrossRefGoogle Scholar
  50. Torniainen M, Mittendorfer-Rutz E, Tanskanen A et al (2015) Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull 41: 656–636CrossRefGoogle Scholar
  51. Wimberley T, MacCabe JH, Laursen TM et al (2017) Mortality and selfharm in association with clozapine in treatment-resistant schizophrenia. Am J Psychiatry 174: 990–998CrossRefGoogle Scholar
  52. Yoshimura B, Sakamoto S, Sato K et al (2017) Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: secondary analysis of an observational study. Early Interv Psychiatry 250: 65–70Google Scholar
  53. Zeller S, Zun L, Cassella JV et al (2017) Response to inhaled loxapine in patients with schizophrenia or bipolar I disorder: PANSS-EC responder analyses. BJPsych Open 3(6): 285–290CrossRefGoogle Scholar
  54. Zheng W, Wang S, Ungvari GS et al (2017) Amantadine for antipsychotic-related weight gain: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 37(3): 341–346CrossRefGoogle Scholar
  55. Zhu Y, Krause M, Huhn M et al (2017) Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry 4(9): 694–705CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2019

Authors and Affiliations

  1. 1.BerlinDeutschland
  2. 2.MainzDeutschland

Personalised recommendations